XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 25.68

-1.8%

11:22 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (10627)	7/7/1999 1:16:00 AM
From: Slugger	Read Replies (1) of 17367

But, even while unblinding sooner rather than later is not risk free for XOMA, enrollment during the last month was slow and IMO if the drug can't win approval based on the 10 day and 60 day data for all and the 90 day data for 90% of the subjects then inclusion of the 90 day data for the remaining 10% is not going to get the drug approved. It has most likely been 90 days or more since the last enrolled patient died. We know XOMA was saying in March that they were close to reaching the target mortality number, so the data they will be losing is that of survivors and half of those received BPI and half placebo. It shouldn't effect final results.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next